Sharekhan

Astec Lifesciences Ltd

Thu 13/03/2025,15:59:8 | NSE : ASTEC

₹ 653.90-38.45 (-5.55%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 697.50

Previous Close

₹ 692.35

Volume

75866

Mkt Cap ( Rs. Cr)

₹1282.39

High

₹ 707.45

Low

₹ 650.00

52 Week High

₹ 1474.40

52 Week Low

₹ 647.50

Book Value Per Share

₹ 148.64

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Astec Lifesciences Ltd

Your Vote -

Buy

62.50%

Hold

25.00%

Sell

12.50%

62.50%

16 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

653.90

7

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

7

Option Chain

Analyzes market sentiment, predicts Astec Lifesciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Astec Lifesciences L - Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 Regarding Sale Of Vacant Office Premi

    12 Mar 2025, 6:20PM Please find enclosed intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding sale of vacant Office Premises.
  • Astec Lifesciences L - General Updates

    12 Mar 2025, 6:18PM Astec LifeSciences Limited has informed the Exchange about General Updates
  • Astec Lifesciences L - Reply to Clarification- Financial results

    12 Mar 2025, 5:56PM The Exchange had sought clarification from Astec LifeSciences Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Lis
  • Astec Lifesciences L - Clarification - Financial Results

    5 Mar 2025, 10:55AM The Exchange has sought clarification from Astec LifeSciences Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Lis
  • Astec Lifesciences L - Copy of Newspaper Publication

    11 Feb 2025, 4:55PM Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
  • Astec Lifesciences L - Integrated Filing (Financial)

    10 Feb 2025, 8:08PM Please find enclosed Integrated filing- Financials, for the Quarter and Nine Months' period ended on December 31, 2024
  • Astec Lifesciences L - Integrated Filing- Financial

    10 Feb 2025, 7:59PM Please find enclosed Integrated Filing- Financials, for the Quarter and Nine Months' period ended December 31, 2024
  • Astec Lifesciences L - Notice Of Shareholders Meetings-XBRL

    10 Feb 2025, 7:53PM Astec LifeSciences Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
  • Astec Lifesciences L - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    10 Feb 2025, 7:48PM Please find enclosed copy of Postal Ballot Notice dispatched today i.e. 10th February, 2025
  • Astec Lifesciences L - Shareholders meeting

    10 Feb 2025, 7:42PM Astec LifeSciences Limited has informed the Exchange regarding Notice of Postal Ballot
  • Astec Lifesciences L - Copy of Newspaper Publication

    28 Jan 2025, 6:12PM Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
  • Astec Lifesciences L - Acquisition-XBRL

    28 Jan 2025, 6:00PM Astec LifeSciences Limited has informed the Exchange regarding Acquisition
  • Astec Lifesciences L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    27 Jan 2025, 7:13PM ASTEC LIFESCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer
  • Astec Lifesciences L - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    27 Jan 2025, 6:42PM Press Release of Unaudited Financial Results for the Quarter ended December 31, 2024.
  • Astec Lifesciences L - Press Release

    27 Jan 2025, 6:41PM Astec LifeSciences Limited has informed the Exchange regarding a press release dated January 27, 2025, titled ""Press Release"".
  • Astec Lifesciences L - Others

    27 Jan 2025, 6:38PM Astec LifeSciences Limited has informed the Exchange about acquisition
  • Astec Lifesciences L - Intimation Of Proposed Acquisition Of 26% Equity Shareholding In Proposed Special Purpose Vehicle

    27 Jan 2025, 6:34PM Please find enclosed the intimation of proposed acquisition of 26% Equity shareholding in proposed Special Purpose Vehicle
  • Astec Lifesciences L - Re-Appointment Of Independent Director

    27 Jan 2025, 6:20PM Please find enclosed the intimation of re-appointment of Independent Director.
  • Astec Lifesciences L - Intimation Of Grant Of Stock Options

    27 Jan 2025, 6:09PM Please find enclosed Intimation of Grant of Stock Options.
  • Astec Lifesciences L - General Updates

    27 Jan 2025, 6:08PM Astec LifeSciences Limited has informed the Exchange about conduct of Postal Ballot
  • Astec Lifesciences L - Intimation For Conduct Of Postal Ballot For Seeking Approval Of The Shareholders For Re-Appointment Of

    27 Jan 2025, 6:04PM Please find enclosed intimation for conduct of Postal Ballot for seeking Approval of Shareholders for Re-appointment of Independent Director.
  • Astec Lifesciences L - General Updates

    27 Jan 2025, 6:02PM Astec LifeSciences Limited has informed the Exchange about General Updates
  • Astec Lifesciences L - Appointment

    27 Jan 2025, 6:02PM Astec LifeSciences Limited has informed the Exchange regarding re-ppointment of Mr Rishinaradamangalam Ramakrishna Govindan as Independent Director of
  • Astec Lifesciences L posts Q3 net loss of Rs 40.40 cr

    27 Jan 2025, 6:00PM The company reported standalone net loss during the quarter stood at Rs 40.40 crore as compared to net loss of Rs 24.35 crore in the previous year qua
  • Astec Lifesciences L - Outcome Of The Board Meeting Held On Monday, 27Th January, 2025

    27 Jan 2025, 5:48PM Kindly find enclosed the Unaudited Financial Results of the Company for the Quarter ended December 31, 2024
  • Astec Lifesciences L - Financial Result Updates

    27 Jan 2025, 5:48PM Astec LifeSciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Astec Lifesciences L - Outcome of Board Meeting

    27 Jan 2025, 5:42PM Please find enclosed outcome of the Board Meeting held on January 27, 2025
  • Astec Lifesciences L - Outcome of Board Meeting

    27 Jan 2025, 5:41PM Astec LifeSciences Limited has informed the Exchange regarding Board meeting held on January 27, 2025.
  • Astec Lifesciences L - Announcement under Regulation 30 (LODR)-Acquisition

    27 Jan 2025, 5:57PM Please find enclosed Intimation of proposed acquisition of 26% Equity shareholding in proposed Special Purpose Vehicle.
  • Astec Lifesciences L - Announcement under Regulation 30 (LODR)-Change in Directorate

    27 Jan 2025, 5:52PM Please find enclosed Intimation of re-appointment of Independent Director for a second term.
  • Astec Lifesciences L - Board Meeting Outcome for Outcome Of The Board Meeting Held On Monday, 27Th January, 2025

    27 Jan 2025, 5:45PM Kindly find enclosed the Outcome of the Board Meeting held on Monday, 27th January, 2025
  • Astec Lifesciences L - Board Meeting Intimation

    20 Jan 2025, 4:29PM ASTEC LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 27-Jan-2025 to inter-alia consider and approve the Unaudited Fi
  • Astec Lifesciences L - Board Meeting Intimation for Intimation Of Board Meeting For Approving The Standalone And Consolidated

    20 Jan 2025, 3:59PM ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consid
  • Astec Lifesciences L has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    9 Jan 2025, 6:30PM As of December 2024, 66.74% is owned by Indian Promoters and 33.25% by Public. <p align=justify> Top two Promoters holding highest number of shares of
  • Astec Lifesciences L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Jan 2025, 5:10PM Kindly find enclosed the Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended December 31, 2024.
  • Astec Lifesciences L - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Jan 2025, 5:09PM Astec LifeSciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter en
  • Astec Lifesciences L - Updates

    8 Jan 2025, 4:33PM kotak Mahindra Capital Company Ltd has submitted to the Exchange a copy of Post offer advertisement in accordance with Regulation 18(12) of the secu
  • Astec Lifesciences L - Updates on Open Offer

    8 Jan 2025, 4:18PM Kotak Mahindra Capital Company Ltd (\Manager to the Offer\) has submitted to BSE a copy of Post Offer Advertisement in accordance with Regulation 18(1
  • Astec Lifesciences L - General Updates

    7 Jan 2025, 6:29PM Astec LifeSciences Limited has informed the Exchange with respect to Intimation under Regulation 30 of the Securities and Exchange Board of India (Lis
  • Astec Lifesciences L - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And

    7 Jan 2025, 6:26PM Kindly find enclosed the intimation of resignation of a Senior Management Personnel (SMP).
  • Astec Lifesciences L - Spurt in Volume

    6 Jan 2025, 11:28AM Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant i
  • Astec Lifesciences L - Spurt in Volume

    3 Jan 2025, 5:58PM Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant i
  • Astec Lifesciences L - Trading Window-XBRL

    24 Dec 2024, 6:43PM ASTEC LIFESCIENCES LIMITED has informed the Exchange about Closure of Trading Window
  • Astec Lifesciences L - Trading Window

    24 Dec 2024, 6:39PM Astec LifeSciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation
  • Astec Lifesciences L - General Updates

    19 Dec 2024, 7:55PM Astec LifeSciences Limited has informed the Exchange about Appointment of Senior Management Personnel
  • Astec Lifesciences L - Intimation Of Appointment Of Senior Management Personnel

    19 Dec 2024, 7:49PM Kindly find enclosed the intimation of appointment of Senior Management Personnel.
  • Astec Lifesciences L - Shareholders meeting

    16 Dec 2024, 2:39PM Astec LifeSciences Limited has informed the Exchange regarding voting results of Postal Ballot

Key fundamentals

Evaluate the intrinsic value of Astec Lifesciences Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 862.5712 759.9738 675.3541 495.7336 345.1506
Liabilities 862.5712 759.9738 675.3541 495.7336 345.1506
Equity 19.6092 19.6057 19.5976 19.5876 19.5684
Gross Profit -5.9027 76.265 154.0835 111.5063 85.2043
Net Profit -46.9871 25.5204 89.818 64.6925 47.4719
Cash From Operating Activities 10.1314 74.3232 23.412 -8.0619 168.5612
NPM(%) -10.25 4.06 13.27 11.65 9.09
Revenue 458.1807 628.1662 676.5661 554.8721 522.2209
Expenses 464.0834 551.9012 522.4826 443.3658 437.0166
ROE(%) -16.11 8.75 30.81 22.19 16.28

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
21 Jul 2023 1.5 15 0 1351.65
19 Jul 2022 1.5 15 0 1950.65
22 Jul 2021 1.5 15 0 1156.65
16 Jul 2020 1.5 15 0 435.35
18 Jul 2019 1.5 15 0 507.05
19 Jul 2018 1.5 15 0 691.25
17 Jul 2017 1.5 15 0 596.25
15 Sep 2015 1.25 12.5 0 165.5
15 Sep 2014 1 10 0 43.3
02 Sep 2013 0.75 7.5 0 18.55
13 Sep 2012 0.5 5 0 25.05
15 Sep 2011 0.5 5 0 46.8
12 Aug 2010 1 10 0 57.35

Peers

Other companies within the same industry or sector that are comparable to Astec Lifesciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 373.76 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 1361.95 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 702.00 2.31 0.00
Suraksha Diagnostic Ltd 278.10 7.02 46.51 45.19 226.82 0.00

Company Info

Our Company was incorporated on January 25, 1994 under the Companies Act, 1956 as Urshila Traders Private Limited. Our Company was originally promoted by Mrs. Reena Bagai and Mrs. Avita Fernandes. Their shareholding was purchased by Mr. Ashok V Hiremath and Mr. Pratap Garud on February 11, 1994. The name of our Company was changed to Astec Chemicals Private Limited on August 19, 1994 and further to Astec LifeSciences Private Limited on March 3, 2006. With effect from April 27, 2006, Astec LifeSciences Private Limited was converted into a public limited company under the name of "Astec LifeSciences Limited". We carry out our manufacturing activities at two locations in Maharashtra, India comprising of three units in Maharashtra viz. one unit at Dombivli and two units at Mahad (Unit 1 and Unit 2). We started our first manufacturing unit in August 1994 by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. With a view to expand our operations, we entered into an agreement with Behram Chemicals Private Limited on February 18, 2002 for using and operating their manufacturing facilities located at B-16, Mahad Industrial Area, Sub-District Mahad, District Raigad, Maharashtra. Behram Chemicals Private Limited was engaged in manufacture of chemicals and pesticides having an installed capacity of 130 MT. Behram Chemicals Private Limited was initially promoted by Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma in April, 1993. During August, 1998 further shares were allotted to M.C. Chemicals and some members of Gangani family viz. Mr. Nasrudin K Gangani, Mr. S. N. Gangani, Mrs. N. N. Gangani, Mr. T. K. Gangani and Khoja Bone Mills Private Limited (a company promoted by Gangani family). Looking at the potential in Behram Chemicals Private Limited, our Company have acquired 65.63% share by entering into Share Purchase Agreement with the above members of Gangani family on April 2, 2007. Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma, M.C. Chemicals and Gangani family are not related to our Promoters / our Directors in any manner in any capacity whatsoever. With this acquisition, Behram Chemicals Private Limited became a subsidiary of our Company. During 2003-04 we expanded total installed capacity of our units (Dombivli and Mahad) from 250 MT to 500 MT. We renewed the agreement on August 1, 2004 for a further period of 66 months ending on January 31, 2010. For more details in respect of the current agreement. In 2004, we acquired a plot located at B-17, Mahad, Maharashtra and set up a new manufacturing facility as an Export Oriented Unit (EOU) in the year 2005 (as Unit 2) which is located adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2 our total installed capacity increased to 1500 MT. We further expanded our total capacities to 2000 MT during 2006- 07 and to 2500 MT during 2007-08. Our Company is primarily involved in the production of active ingredients and intermediates for agrochemicals and pharmaceutical segment. Hexaconazole, Tebuconazole, Metalaxyl and Propiconazole are some of our key products in agrochemical segment which are generally used in crop protection and Dicap is one of our key Pharmaceutical intermediate which is used in manufacture of antifungal agents. Triazole fungicides, which includes Hexaconazole, Tebuconazole, and Propiconazole is one of our major product in the agrochemical segment, and has contributed 63.67% to our total sales whereas Dicap, a key product in pharmaceutical segment has contributed 9.01% during FY 2007-08. Major events of our Company Period Events January 1994 Incorporation of Urshila Traders Private Limited August 1994 Change of name to Astec Chemicals Private Limited August 1994 Commenced first manufacturing unit at Dombivli, Maharashtra May, 2001 Certified ISO 9002 by International Standards Certification Pty Limited, Australia February 2002 Entered into an agreement with Behram Chemicals Private Limited March 2005 Re-certified ISO 9001:2000 by International Standards Certification Pty Limited, Australia May 2005 Commenced another manufacturing unit (Unit 2) as Export Oriented Unit at Mahad, Maharashtra March 2006 Change of name to Astec LifeSciences Private Limited April 2006 Conversion of our Company from a private limited company to a public limited company January 2007 Established Astec Europe in Tournai, Belgium April 2007 Behram Chemicals Private Limited became our subsidiary by acquisition of 65.63% vide Share Purchase Agreement dated April 2, 2007 2011 -Registered Office of the Company has been shifted 5, 5-A, 4th Floor, Kamanwala Chambers, Sir P. M. Road, Fort, Mumbai - 400001 To Elite Square, 7th Floor, 274, Perin Nariman Street, Fort, Mumbai - 400001. 2012 - Astec has entered into an exclusive long term contract with a multinational company to manufacture and supply a fungicide - Astec Recommended a dividend of fifty paise per share (i.e. 5% on the face value of Rs.10/- each) 2013 -Astec Lifesciences Ltd has Recommended a dividend of Seventy Five paise per share (i.e. 7.5% on face value of Rs. 10/- each). -Mr. Ravindra Inani as Chief Financial Officer (CFO) of the Company. 2014 -Appointed Dr. Leena Raje as the new Woman Director. -Astec Lifesciences Ltd has recommend enhanced dividend of Rupee One per share (i.e. 10% on the face value of Rs. 10/- each. 2017 -Astec Lifesciences Ltd was received Certificate of Merit for Performance in Industrial Safety 2017 2018 -Astec Lifesciences Ltd Wins Indian Chemical Council (ICC) Award For Excellence In Management --Astec Lifesciences Ltd amalgametted with Godrej Agrovet Limited 2019 -Astec Lifesciences Ltd was awared ICC Award for Excellence in Human Resource Management 2020 -Astec Lifesciences Ltd is stake entire equity in Astec Europe Sprl 2021 -Astec LifeSciences Limited commenced commercial production at its new Herbicide plant at Mahad 2023 -Astec LifeSciences launches Rs. 100 crore Adi Godrej Center for Chemical Research and Development. -Astec LifeSciences launches R&D Center to develop new crop protection formulations.

Our Company was incorporated on January 25, 1994 under the Companies Act, 1956 as Urshila Traders Private Limited. Our Company was originally promoted by Mrs. Reena Bagai and Mrs. Avita Fernandes. Their shareholding was purchased by Mr. Ashok V Hiremath and Mr. Pratap Garud on February 11, 1994. The name of our Company was changed to Astec Chemicals Private Limited on August 19, 1994 and further to Astec LifeSciences Private Limited on March 3, 2006. With effect from April 27, 2006, Astec LifeSciences Private Limited was converted into a public limited company under the name of "Astec LifeSciences Limited". We carry out our manufacturing activities at two locations in Maharashtra, India comprising of three units in Maharashtra viz. one unit at Dombivli and two units at Mahad (Unit 1 and Unit 2). We started our first manufacturing unit in August 1994 by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. With a view to expand our operations, we entered into an agreement with Behram Chemicals Private Limited on February 18, 2002 for using and operating their manufacturing facilities located at B-16, Mahad Industrial Area, Sub-District Mahad, District Raigad, Maharashtra. Behram Chemicals Private Limited was engaged in manufacture of chemicals and pesticides having an installed capacity of 130 MT. Behram Chemicals Private Limited was initially promoted by Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma in April, 1993. During August, 1998 further shares were allotted to M.C. Chemicals and some members of Gangani family viz. Mr. Nasrudin K Gangani, Mr. S. N. Gangani, Mrs. N. N. Gangani, Mr. T. K. Gangani and Khoja Bone Mills Private Limited (a company promoted by Gangani family). Looking at the potential in Behram Chemicals Private Limited, our Company have acquired 65.63% share by entering into Share Purchase Agreement with the above members of Gangani family on April 2, 2007. Mr. Jehangir J. Mistry, Mrs. Villoo J. Mistry, Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma, M.C. Chemicals and Gangani family are not related to our Promoters / our Directors in any manner in any capacity whatsoever. With this acquisition, Behram Chemicals Private Limited became a subsidiary of our Company. During 2003-04 we expanded total installed capacity of our units (Dombivli and Mahad) from 250 MT to 500 MT. We renewed the agreement on August 1, 2004 for a further period of 66 months ending on January 31, 2010. For more details in respect of the current agreement. In 2004, we acquired a plot located at B-17, Mahad, Maharashtra and set up a new manufacturing facility as an Export Oriented Unit (EOU) in the year 2005 (as Unit 2) which is located adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2 our total installed capacity increased to 1500 MT. We further expanded our total capacities to 2000 MT during 2006- 07 and to 2500 MT during 2007-08. Our Company is primarily involved in the production of active ingredients and intermediates for agrochemicals and pharmaceutical segment. Hexaconazole, Tebuconazole, Metalaxyl and Propiconazole are some of our key products in agrochemical segment which are generally used in crop protection and Dicap is one of our key Pharmaceutical intermediate which is used in manufacture of antifungal agents. Triazole fungicides, which includes Hexaconazole, Tebuconazole, and Propiconazole is one of our major product in the agrochemical segment, and has contributed 63.67% to our total sales whereas Dicap, a key product in pharmaceutical segment has contributed 9.01% during FY 2007-08. Major events of our Company Period Events January 1994 Incorporation of Urshila Traders Private Limited August 1994 Change of name to Astec Chemicals Private Limited August 1994 Commenced first manufacturing unit at Dombivli, Maharashtra May, 2001 Certified ISO 9002 by International Standards Certification Pty Limited, Australia February 2002 Entered into an agreement with Behram Chemicals Private Limited March 2005 Re-certified ISO 9001:2000 by International Standards Certification Pty Limited, Australia May 2005 Commenced another manufacturing unit (Unit 2) as Export Oriented Unit at Mahad, Maharashtra March 2006 Change of name to Astec LifeSciences Private Limited April 2006 Conversion of our Company from a private limited company to a public limited company January 2007 Established Astec Europe in Tournai, Belgium April 2007 Behram Chemicals Private Limited became our subsidiary by acquisition of 65.63% vide Share Purchase Agreement dated April 2, 2007 2011 -Registered Office of the Company has been shifted 5, 5-A, 4th Floor, Kamanwala Chambers, Sir P. M. Road, Fort, Mumbai - 400001 To Elite Square, 7th Floor, 274, Perin Nariman Street, Fort, Mumbai - 400001. 2012 - Astec has entered into an exclusive long term contract with a multinational company to manufacture and supply a fungicide - Astec Recommended a dividend of fifty paise per share (i.e. 5% on the face value of Rs.10/- each) 2013 -Astec Lifesciences Ltd has Recommended a dividend of Seventy Five paise per share (i.e. 7.5% on face value of Rs. 10/- each). -Mr. Ravindra Inani as Chief Financial Officer (CFO) of the Company. 2014 -Appointed Dr. Leena Raje as the new Woman Director. -Astec Lifesciences Ltd has recommend enhanced dividend of Rupee One per share (i.e. 10% on the face value of Rs. 10/- each. 2017 -Astec Lifesciences Ltd was received Certificate of Merit for Performance in Industrial Safety 2017 2018 -Astec Lifesciences Ltd Wins Indian Chemical Council (ICC) Award For Excellence In Management --Astec Lifesciences Ltd amalgametted with Godrej Agrovet Limited 2019 -Astec Lifesciences Ltd was awared ICC Award for Excellence in Human Resource Management 2020 -Astec Lifesciences Ltd is stake entire equity in Astec Europe Sprl 2021 -Astec LifeSciences Limited commenced commercial production at its new Herbicide plant at Mahad 2023 -Astec LifeSciences launches Rs. 100 crore Adi Godrej Center for Chemical Research and Development. -Astec LifeSciences launches R&D Center to develop new crop protection formulations.

Read More

Parent Organisation

Astec Lifesciences Ltd.

Founded

25/01/1994

Managing Director

Mr.Nadir B Godrej

NSE Symbol

ASTECEQ

FAQ

The current price of Astec Lifesciences Ltd is ₹ 653.90.

The 52-week high for Astec Lifesciences Ltd is ₹ 707.45 and the 52-week low is ₹ 650.00.

The market capitalization of Astec Lifesciences Ltd is currently ₹ 1282.39. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Astec Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Astec Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Astec Lifesciences Ltd shares.

The CEO of Astec Lifesciences Ltd is Mr.Nadir B Godrej, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT